Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Ardelyx will hold a conference call on May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update for the first quarter of 2025 [1] - Participants can join the call by dialing (877) 346-6112 for domestic calls or (848) 280-6350 for international calls [2] - The conference call will be available via live audio webcast on the company's website and will be archived for 30 days [2]